218 related articles for article (PubMed ID: 27259012)
41. Cutaneous metastases from breast carcinoma: calretinin expression and estrogen, progesterone and Her2/neu status of the metastases, compared to primary cutaneous apocrine tumors.
Fernandez-Flores A
Rom J Morphol Embryol; 2013; 54(3 Suppl):695-9. PubMed ID: 24322014
[TBL] [Abstract][Full Text] [Related]
42. Clinicopathological characteristics of the SOX10+ subset of HER2+ breast cancer.
Weisman P; Yu Q; Xu J
Ann Diagn Pathol; 2023 Apr; 63():152087. PubMed ID: 36669230
[TBL] [Abstract][Full Text] [Related]
43. Expression of 5α-reductase in apocrine carcinoma of the breast and its correlation with clinicopathological aggressiveness.
Kasashima S; Kawashima A; Ozaki S; Nakanuma Y
Histopathology; 2012 May; 60(6B):E51-7. PubMed ID: 22486281
[TBL] [Abstract][Full Text] [Related]
44. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
45. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
[TBL] [Abstract][Full Text] [Related]
46. Triple negative breast cancer: clinical characteristics in the different histological subtypes.
Dreyer G; Vandorpe T; Smeets A; Forceville K; Brouwers B; Neven P; Janssens H; Deraedt K; Moerman P; Van Calster B; Christiaens MR; Paridaens R; Wildiers H
Breast; 2013 Oct; 22(5):761-6. PubMed ID: 23416046
[TBL] [Abstract][Full Text] [Related]
47. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
Peng Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
[TBL] [Abstract][Full Text] [Related]
48. Apocrine adenocarcinoma of the breast: A rare special subtype with divergent theranostic markers.
Sujata S; Sudeep K; Taruna Y; Mahendra L
J Cancer Res Ther; 2023; 19(2):477-479. PubMed ID: 37313919
[TBL] [Abstract][Full Text] [Related]
49. Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype.
Titloye NA; Foster A; Omoniyi-Esan GO; Komolafe AO; Daramola AO; Adeoye OA; Adisa AO; Manoharan A; Pathak D; D'Cruz MN; Alizadeh Y; Lewis PD; Shaaban AM
Pathobiology; 2016; 83(1):24-32. PubMed ID: 26730581
[TBL] [Abstract][Full Text] [Related]
50. Apocrine carcinoma of the breast: a comprehensive review.
Vranic S; Schmitt F; Sapino A; Costa JL; Reddy S; Castro M; Gatalica Z
Histol Histopathol; 2013 Nov; 28(11):1393-409. PubMed ID: 23771415
[TBL] [Abstract][Full Text] [Related]
51. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers.
Safarpour D; Tavassoli FA
Arch Pathol Lab Med; 2015 May; 139(5):612-7. PubMed ID: 25310144
[TBL] [Abstract][Full Text] [Related]
52. Utility of Sox10 labeling in metastatic breast carcinomas.
Nelson ER; Sharma R; Argani P; Cimino-Mathews A
Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
[TBL] [Abstract][Full Text] [Related]
53. p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?
Wang X; Stolla M; Ring BZ; Yang Q; Laughlin TS; Rothberg PG; Skinner K; Hicks DG
Hum Pathol; 2016 Sep; 55():196-201. PubMed ID: 27246177
[TBL] [Abstract][Full Text] [Related]
54. Expression of oestrogen receptor-beta in apocrine carcinomas of the breast.
Honma N; Takubo K; Akiyama F; Kasumi F; Sawabe M; Arai T; Hosoi T; Yoshimura N; Harada N; Younes M; Sakamoto G
Histopathology; 2007 Mar; 50(4):425-33. PubMed ID: 17448017
[TBL] [Abstract][Full Text] [Related]
55. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
[TBL] [Abstract][Full Text] [Related]
56. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?
Safarpour D; Pakneshan S; Tavassoli FA
Am J Cancer Res; 2014; 4(4):353-68. PubMed ID: 25057438
[TBL] [Abstract][Full Text] [Related]
57. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
[TBL] [Abstract][Full Text] [Related]
58. Histological and immunohistochemical analysis of apocrine breast carcinoma.
Matsuo K; Fukutomi T; Hasegawa T; Akashi-Tanaka S; Nanasawa T; Tsuda H
Breast Cancer; 2002; 9(1):43-9. PubMed ID: 12196721
[TBL] [Abstract][Full Text] [Related]
59. Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors.
Selim AG; Wells CA
J Clin Pathol; 1999 Nov; 52(11):838-41. PubMed ID: 10690175
[TBL] [Abstract][Full Text] [Related]
60. FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast.
Gromov P; Espinoza JA; Talman ML; Honma N; Kroman N; Timmermans Wielenga V; Moreira JM; Gromova I
PLoS One; 2014; 9(11):e112024. PubMed ID: 25389781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
